QQQ   348.27 (-0.49%)
AAPL   178.20 (+0.51%)
MSFT   331.74 (+0.16%)
META   263.32 (+0.30%)
GOOGL   123.21 (-0.37%)
AMZN   120.54 (-0.92%)
TSLA   197.30 (-1.92%)
NVDA   393.79 (-1.82%)
NIO   7.26 (-2.02%)
BABA   78.40 (-0.34%)
AMD   122.07 (-2.55%)
T   15.77 (+0.83%)
F   12.13 (-3.65%)
MU   68.17 (-4.91%)
CGC   0.81 (-4.73%)
GE   100.62 (-1.74%)
DIS   87.40 (-0.48%)
AMC   4.51 (-2.59%)
PFE   37.43 (+1.13%)
PYPL   61.58 (-0.76%)
NFLX   392.11 (-0.22%)
QQQ   348.27 (-0.49%)
AAPL   178.20 (+0.51%)
MSFT   331.74 (+0.16%)
META   263.32 (+0.30%)
GOOGL   123.21 (-0.37%)
AMZN   120.54 (-0.92%)
TSLA   197.30 (-1.92%)
NVDA   393.79 (-1.82%)
NIO   7.26 (-2.02%)
BABA   78.40 (-0.34%)
AMD   122.07 (-2.55%)
T   15.77 (+0.83%)
F   12.13 (-3.65%)
MU   68.17 (-4.91%)
CGC   0.81 (-4.73%)
GE   100.62 (-1.74%)
DIS   87.40 (-0.48%)
AMC   4.51 (-2.59%)
PFE   37.43 (+1.13%)
PYPL   61.58 (-0.76%)
NFLX   392.11 (-0.22%)
QQQ   348.27 (-0.49%)
AAPL   178.20 (+0.51%)
MSFT   331.74 (+0.16%)
META   263.32 (+0.30%)
GOOGL   123.21 (-0.37%)
AMZN   120.54 (-0.92%)
TSLA   197.30 (-1.92%)
NVDA   393.79 (-1.82%)
NIO   7.26 (-2.02%)
BABA   78.40 (-0.34%)
AMD   122.07 (-2.55%)
T   15.77 (+0.83%)
F   12.13 (-3.65%)
MU   68.17 (-4.91%)
CGC   0.81 (-4.73%)
GE   100.62 (-1.74%)
DIS   87.40 (-0.48%)
AMC   4.51 (-2.59%)
PFE   37.43 (+1.13%)
PYPL   61.58 (-0.76%)
NFLX   392.11 (-0.22%)
QQQ   348.27 (-0.49%)
AAPL   178.20 (+0.51%)
MSFT   331.74 (+0.16%)
META   263.32 (+0.30%)
GOOGL   123.21 (-0.37%)
AMZN   120.54 (-0.92%)
TSLA   197.30 (-1.92%)
NVDA   393.79 (-1.82%)
NIO   7.26 (-2.02%)
BABA   78.40 (-0.34%)
AMD   122.07 (-2.55%)
T   15.77 (+0.83%)
F   12.13 (-3.65%)
MU   68.17 (-4.91%)
CGC   0.81 (-4.73%)
GE   100.62 (-1.74%)
DIS   87.40 (-0.48%)
AMC   4.51 (-2.59%)
PFE   37.43 (+1.13%)
PYPL   61.58 (-0.76%)
NFLX   392.11 (-0.22%)
NASDAQ:AXDX

Accelerate Diagnostics (AXDX) Stock Forecast, Price & News

$0.70
+0.02 (+2.96%)
(As of 10:53 AM ET)
Compare
Today's Range
$0.68
▼
$0.70
50-Day Range
$0.47
▼
$0.90
52-Week Range
$0.45
▼
$3.74
Volume
24,076 shs
Average Volume
273,378 shs
Market Capitalization
$69.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Accelerate Diagnostics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
4.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.62
Upright™ Environmental Score
News Sentiment
0.43mentions of Accelerate Diagnostics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$139,390 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.59) to ($0.52) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

726th out of 1,006 stocks

Analytical Instruments Industry

19th out of 29 stocks

See Top Rated MarketRank™ Stocks Here

AXDX stock logo

About Accelerate Diagnostics (NASDAQ:AXDX) Stock

Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded in 1982 and is headquartered in Tucson, AZ.

Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

AXDX Stock News Headlines

May 18, 2023 | americanbankingnews.com
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com
May 12, 2023 | finanznachrichten.de
Accelerate Diagnostics, Inc.: Accelerate Diagnostics Reports First Quarter 2023 Financial Results
May 31, 2023 | Edge On The Street (Ad)
AI Getting Close to Thinking Like Humans
Technology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.
May 11, 2023 | msn.com
Recap: Accelerate Diagnostics Q1 Earnings
May 11, 2023 | finance.yahoo.com
Accelerate Diagnostics Reports First Quarter 2023 Financial Results
May 11, 2023 | finance.yahoo.com
Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement
May 10, 2023 | markets.businessinsider.com
Accelerate Diagnostics is about to announce its earnings — here's what Wall Street expects
May 9, 2023 | americanbankingnews.com
Accelerate Diagnostics (AXDX) Scheduled to Post Quarterly Earnings on Thursday
May 31, 2023 | Edge On The Street (Ad)
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
April 27, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), SurModics (SRDX) and Accelerate Diagnostics (AXDX)
April 27, 2023 | finance.yahoo.com
Accelerate Diagnostics scheduled call to review 2023 first quarter results
April 17, 2023 | finance.yahoo.com
Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) 38% Jump Shows Its Popularity With Investors
April 4, 2023 | americanbankingnews.com
Q1 2023 EPS Estimates for Accelerate Diagnostics, Inc. Decreased by Analyst (NASDAQ:AXDX)
April 3, 2023 | finance.yahoo.com
Accelerate Diagnostics (AXDX) Upgraded to Buy: What Does It Mean for the Stock?
April 3, 2023 | americanbankingnews.com
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Short Interest Update
April 1, 2023 | finance.yahoo.com
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2022 Earnings Call Transcript
March 31, 2023 | americanbankingnews.com
Accelerate Diagnostics, Inc. to Post Q1 2024 Earnings of ($0.16) Per Share, William Blair Forecasts (NASDAQ:AXDX)
March 30, 2023 | finanznachrichten.de
Accelerate Diagnostics, Inc.: Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results
March 30, 2023 | americanbankingnews.com
Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by StockNews.com
March 29, 2023 | msn.com
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
March 29, 2023 | finance.yahoo.com
Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results
March 28, 2023 | markets.businessinsider.com
Craig-Hallum Keeps Their Hold Rating on Accelerate Diagnostics (AXDX)
March 27, 2023 | americanbankingnews.com
Accelerate Diagnostics (AXDX) to Release Earnings on Wednesday
March 15, 2023 | finance.yahoo.com
Accelerate Diagnostics scheduled call to review 2022 fourth quarter and full year results
March 8, 2023 | finance.yahoo.com
Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors
February 19, 2023 | marketwatch.com
Allergy Diagnostics Market New Insight Report 2023: Estimated to Accelerate Industry Growth with SWOT Analysis, Top Players, and Outlook 2029
February 10, 2023 | theglobeandmail.com
Closing Bell: Accelerate Absolute Return Hdg Fund ETF flat on Friday (HDGE)
See More Headlines
Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

AXDX Company Calendar

Last Earnings
3/29/2023
Today
5/31/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXDX
CUSIP
N/A
CIK
727207
Web
acceleratediagnostics.com
Phone
(520) 365-3100
Fax
520-269-6580
Employees
220
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-62,490,000.00
Net Margins
-516.49%
Pretax Margin
-522.81%
Return on Equity
N/A
Return on Assets
-105.39%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.63
Quick Ratio
0.55

Sales & Book Value

Annual Sales
$12.75 million
Price / Sales
5.29
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.22) per share
Price / Book
-3.07

Miscellaneous

Outstanding Shares
99,830,000
Free Float
57,703,000
Market Cap
$67.39 million
Optionable
Optionable
Beta
1.18

Key Executives

  • Jack PhillipsJack Phillips
    President, Chief Executive Officer & Director
  • Maya Gowri
    Head-Operations & Senior Vice President
  • David Patience
    Chief Financial Officer
  • Lawrence Mertz
    Chief Technology Officer
  • Gretchen Strohminger
    Senior VP, Head-Human Resources & Culture

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AXDX Stock - Frequently Asked Questions

Should I buy or sell Accelerate Diagnostics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AXDX shares.
View AXDX analyst ratings or view top-rated stocks.

How have AXDX shares performed in 2023?

Accelerate Diagnostics' stock was trading at $0.7060 at the start of the year. Since then, AXDX shares have decreased by 4.4% and is now trading at $0.6750.
View the best growth stocks for 2023 here.

When is Accelerate Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our AXDX earnings forecast.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) released its quarterly earnings data on Wednesday, March, 29th. The medical research company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.02. The medical research company had revenue of $2.97 million for the quarter, compared to the consensus estimate of $3 million.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by many different institutional and retail investors. Top institutional investors include Griffin Asset Management Inc. (10.29%), Tejara Capital Ltd (0.36%), Allworth Financial LP (0.15%), TCI Wealth Advisors Inc. (0.09%), Chartist Inc. CA (0.07%) and Price T Rowe Associates Inc. MD (0.06%). Insiders that own company stock include David Patience, Hany Massarany, Jack Phillips, Jack W Schuler, Larry Michael Mertz, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $0.68.

How much money does Accelerate Diagnostics make?

Accelerate Diagnostics (NASDAQ:AXDX) has a market capitalization of $67.39 million and generates $12.75 million in revenue each year. The medical research company earns $-62,490,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.

How many employees does Accelerate Diagnostics have?

The company employs 220 workers across the globe.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The official website for the company is acceleratediagnostics.com. The medical research company can be reached via phone at (520) 365-3100, via email at investors@axdx.com, or via fax at 520-269-6580.

This page (NASDAQ:AXDX) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -